EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the “Rebiopsy on Osi” study)

Eleonora Gariazzo, Francesca Colamartini, Ornella Cantale, Andrea Mogavero, Antonio Vitale, Luca Romano, Marianna Peroni, Erika Rijavec, Marco Banini, Sofia Mazzoni, Mirko Montrone, Giulia Pasello, Antonello Veccia, Francesca Rita Ogliari, Silvana Leo, Diego Cortinovis, Angelo Delmonte, Lorenzo Belluomini, Giulia La Cava, Giulia Meoni, Claudio Sini, Marco Donatello Delcuratolo, Anna Bettini, Maria Pagano, Carlo Genova, Alessandro Russo, Giacomo Pelizzari, Luca Tondulli, Concetta Sergi, Elisa Roca, Chiara Bennati, Salvatore Grisanti, Brigida Stanzione, Sabrina Mariotti, Tiziana Vavalà, Hector Soto Parra, Cinzia Ortega, Daniele Pignataro, Gaetano Lacidogna, Maria Simona Pino · 2026

Read EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the “Rebiopsy on Osi” study) by Eleonora Gariazzo, Francesca Colamartini, Ornella Cantale, Andrea Mogavero, Antonio Vitale, Luca Romano, Marianna Peroni, Erika Rijavec, Marco Banini, Sofia Mazzoni, Mirko Montrone, Giulia Pasello, Antonello Veccia, Francesca Rita Ogliari, Silvana Leo, Diego Cortinovis, Angelo Delmonte, Lorenzo Belluomini, Giulia La Cava, Giulia Meoni, Claudio Sini, Marco Donatello Delcuratolo, Anna Bettini, Maria Pagano, Carlo Genova, Alessandro Russo, Giacomo Pelizzari, Luca Tondulli, Concetta Sergi, Elisa Roca, Chiara Bennati, Salvatore Grisanti, Brigida Stanzione, Sabrina Mariotti, Tiziana Vavalà, Hector Soto Parra, Cinzia Ortega, Daniele Pignataro, Gaetano Lacidogna, Maria Simona Pino (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13529361.txt.

Description

Eleonora Gariazzo and co-authors study whether re-testing tumours at progression improves care for lung cancer patients whose EGFR-mutant disease has stopped responding to osimertinib. Their 2026 multicentre retrospective study, called Rebiopsy on Osi, uses an Italian registry of patients on this first-line targeted drug.

Of 457 patients who progressed, 206 had a rebiopsy, mostly tissue sampling. A resistance mechanism was found in 38.8 percent of those tested, with tissue testing detecting far more than blood testing, and MET amplification was the commonest actionable finding. Among patients receiving second-line therapy, those given treatment matched to their rebiopsy result lived longer without progression and overall than patients rebiopsied without adaptation or not rebiopsied at all. Median survival reached 14.1 months with adaptive therapy against 8.2 months without rebiopsy. The authors support routine rebiopsy at progression.

Catalog record

CREATOREleonora Gariazzo, Francesca Colamartini, Ornella Cantale, Andrea Mogavero, Antonio Vitale, Luca Romano, Marianna Peroni, Erika Rijavec, Marco Banini, Sofia Mazzoni, Mirko Montrone, Giulia Pasello, Antonello Veccia, Francesca Rita Ogliari, Silvana Leo, Diego Cortinovis, Angelo Delmonte, Lorenzo Belluomini, Giulia La Cava, Giulia Meoni, Claudio Sini, Marco Donatello Delcuratolo, Anna Bettini, Maria Pagano, Carlo Genova, Alessandro Russo, Giacomo Pelizzari, Luca Tondulli, Concetta Sergi, Elisa Roca, Chiara Bennati, Salvatore Grisanti, Brigida Stanzione, Sabrina Mariotti, Tiziana Vavalà, Hector Soto Parra, Cinzia Ortega, Daniele Pignataro, Gaetano Lacidogna, Maria Simona Pino
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE55 KB
LICENSEhttps://creativecommons.org/licenses/by/4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/article/MED/PMC13529361

Browse the full library · About the Tower of Babel